

## Nursing Care for Patients with Systemic Lupus Erythematosus (SLE)

**Najwa Dahy Alanizi<sup>1</sup>, Alenezi Sameer Moutlaq K.<sup>2</sup>, Aljoufi Ziyad Oqla M.<sup>3</sup>, Jaber Aber Awwadh J. Alhazmi<sup>4</sup>, Khulood Fahd Alaida<sup>5</sup>, Jassem Ahmed Jassem Alghasham<sup>6</sup>, Fahad Sadi Matr Alrashidi<sup>7</sup>, Shahah Awadh Funus Al Shammari<sup>8</sup>, Ali Malhawi Mohammed Sarkhi<sup>9</sup>, Maha Alhumaidia Albanaqi<sup>10</sup>**

<sup>1</sup> Nursing, Qurayyat Mental Health Hospital, Al-Qurayyat, Al-Jouf Region, Saudi Arabia.

<sup>2</sup> Nursing technician, North Medical Tower, Arar, Northern Border Region, Saudi Arabia.

<sup>3</sup> Technician-Nursing, Domat Al-Jandal General Hospital, Domat Al-Jandal, Al-Jouf Region, Saudi Arabia.

<sup>4</sup> Health Assistant, Northern Borders Health Cluster, Northern Border Region, Saudi Arabia.

<sup>5</sup> Nursing, Tayma General Hospital, Tayma, Tabuk Region, Saudi Arabia.

<sup>6</sup> EMERGENCY MEDICAL TECHNICIAN, King Fahad General Hospital, Al-Hofuf, Al-Ahsa, Eastern Region, Saudi Arabia.

<sup>7</sup> Emergency medical technician, Safit Health Services Center, Al-Hayit, Hail Region, Saudi Arabia.

<sup>8</sup> Technician-Nursing, Rafha Hospital, Northern Border Region, Saudi Arabia.

<sup>9</sup> Specialist-Nursing (Nursing and Midwifery), Medical Services Ministry of Interior - Security Forces Hospital, Riyadh, Riyadh Region, Saudi Arabia.

<sup>10</sup> Nursing Technician, Al-Uwayqilah Hospital, Northern Borders Health Cluster, Al-Uwayqilah, Northern Border Region, Saudi Arabia.

### **Abstract:**

Nursing care for patients with Systemic Lupus Erythematosus (SLE) focuses on providing holistic support that addresses both physical and emotional needs. These patients often experience a wide variety of symptoms, including fatigue, joint pain, skin rashes, and renal complications. Nurses play a critical role in assessing symptoms, monitoring disease activity, and educating patients about their condition. Key interventions include administering medications as prescribed, such as corticosteroids and immunosuppressants, while also being vigilant for potential side effects. Regular assessments of vital signs, laboratory tests (like anti-dsDNA and complement levels), and monitoring for flares are essential components of effective care. In addition to physical care, nurses must also support the mental and emotional well-being of SLE patients. Living with a chronic illness can lead to anxiety, depression, and social isolation, making psychosocial support crucial. Nurses should foster open communication, encouraging patients to express their feelings and concerns. Education on lifestyle modifications, such as sun protection and dietary adjustments, can empower patients to manage their condition more effectively. Encouraging participation in support groups and connecting patients with mental health resources can enhance coping mechanisms and improve overall quality of life.

**Keywords:** Systemic Lupus Erythematosus (SLE), Nursing Care, Patient Education, Symptom Management, Medication Administration, Disease Monitoring, Psychosocial Support, Lifestyle Modifications, Chronic Illness Management, Patient Empowerment

### **Introduction:**

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder characterized by the body's immune system erroneously attacking healthy tissues and organs. This multifaceted condition can affect various systems within the body, including the skin, joints, kidneys, heart, and nervous system, leading to a wide range of clinical manifestations and complications. With an estimated prevalence of

20 to 150 cases per 100,000 individuals, SLE predominantly affects women of childbearing age, although it can also occur in men and the elderly. The variable nature of SLE often leads to significant challenges in both diagnosis and management, necessitating a multidisciplinary approach to care. Among the key stakeholders in the management of this chronic disease are nursing professionals, whose role is crucial in ensuring the delivery of comprehensive, patient-centered care [1].

Given the chronic and unpredictable nature of SLE, patients frequently experience fluctuations in disease activity, characterized by periods of exacerbation followed by periods of remission. This variability necessitates careful monitoring and adjustment of treatment protocols to manage symptoms effectively and to mitigate potential organ damage. The complexity of SLE symptoms can often result in psychological distress, reduced quality of life, and increased dependency on healthcare services. Nurses are often on the front lines of patient interaction, allowing them to play pivotal roles in health education, symptom management, and psychosocial support. Therefore, an understanding of the disease, its implications, and the specific nursing interventions tailored to SLE patients is crucial for optimizing patient outcomes [2].

Nursing care for patients with SLE encompasses various responsibilities, including patient assessment, education, and advocacy. Nurses must be well-versed in the diverse manifestations of SLE and the pharmacological and non-pharmacological interventions available. Key areas of focus include pain management, addressing fatigue, promoting adherence to treatment regimens, and providing guidance on lifestyle modifications that can help alleviate symptoms. Effective nursing care can empower patients, enabling them to gain a better understanding of their condition and encouraging them to take an active role in their health management [3].

Moreover, the role of nurses extends to the interdisciplinary collaboration required in the management of SLE. SLE care often involves a range of healthcare professionals, including rheumatologists, nephrologists, dermatologists, physical therapists, and dietitians. Nurses serve as critical liaisons among these providers, ensuring that patient care is coordinated and that patients receive comprehensive support across various disciplines. The assessments and interactions that nurses conduct can often provide insights that inform treatment decisions and adjustments made by other team members [4].

As the understanding of SLE deepens and treatment strategies evolve, nursing education and practices must also adapt to incorporate the latest evidence-based guidelines. Training programs and continuing

education resources focused on SLE can prepare nursing professionals to deliver care that is not only responsive to the clinical needs of the patients but also sensitive to their emotional and psychosocial challenges. Furthermore, ongoing research into SLE and its treatments can arm nurses with the tools necessary to address patient concerns, inform them about new therapies, and advocate for their needs within the healthcare system [5].

The complexity of SLE demands that nursing care remains dynamic, with an emphasis on both physical and emotional well-being. Research indicates that patients with autoimmune disorders report higher rates of anxiety and depression, which can complicate treatment adherence and overall health outcomes. Thus, nurses should be prepared to utilize strategies that not only manage physical symptoms but also promote mental health resilience. This holistic approach to care not only improves the patient experience but can result in better adherence to treatment plans and ultimately, improved health outcomes [6].

#### **Assessment and Diagnosis in SLE Patients:**

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by a diverse array of clinical manifestations that can affect multiple organ systems. This chronic condition primarily affects women, especially those of childbearing age, and presents a unique challenge for healthcare providers in terms of assessment and diagnosis. Due to the varied nature of its symptoms and the overlap with other diseases, SLE is often referred to as a "great imitator." As such, a comprehensive understanding of the assessment and diagnostic process is vital for effective management of SLE patients [7].

SLE is marked by the production of autoantibodies that target various cellular components, leading to widespread inflammation and tissue damage. The hallmark symptoms include, but are not limited to, joint pain, skin rashes (notably the characteristic "butterfly rash"), photosensitivity, and renal involvement. The pathogenesis of SLE is multifactorial, with genetic predisposition, environmental factors, hormonal influences, and immune system dysregulation contributing to the disease. Due to its heterogeneous clinical presentation, SLE can manifest in various ways,

ranging from mild to severe, and can progress unpredictably over time [7].

The assessment of SLE patients involves a meticulous process that begins with a thorough medical history and physical examination. Gathering a comprehensive history is essential, as it provides insights into the symptoms experienced by the patient, their chronological progression, and any potential triggers. Symptoms may include fatigue, fever, weight loss, and joint pain, which can fluctuate significantly over time. A precise understanding of these symptoms, along with their frequency and severity, is crucial for developing an effective diagnostic and treatment plan.

In addition to historical data, a physical examination is integral to the assessment process. Clinicians examine the skin for rashes, assess joints for swelling or tenderness, and evaluate other organ systems that may be affected, such as the kidneys, lungs, and neurological system. Regular monitoring of vital signs and organ function is also essential in the management of SLE, as it allows for the early detection of flare-ups or complications [8].

### Diagnostic Criteria for SLE

The diagnosis of SLE relies on a combination of clinical features and laboratory tests. The American College of Rheumatology (ACR) has established criteria for diagnosing SLE, which include the presence of at least four of the following 11 criteria:

1. Malar rash (butterfly rash)
2. Discoid rash
3. Photosensitivity
4. Oral ulcers
5. Arthritis
6. Serositis (pleuritis or pericarditis)
7. Renal disorder (proteinuria or cellular casts)
8. Neurological disorder (seizures or psychosis)
9. Hematological disorder (hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia)
10. Immunological disorder (anti-dsDNA, anti-Sm, or antiphospholipid antibodies)

11. Presence of antinuclear antibodies (ANA)

Although these criteria serve as a guideline, SLE can still be challenging to diagnose, especially in its early stages, when symptoms may be mild or atypical. Therefore, clinicians often take a holistic approach, considering not only lab results but also the overall clinical picture and patient history [9].

### Laboratory Evaluations

Laboratory testing plays a crucial role in the assessment of SLE. Serological tests are conducted to detect autoantibodies, which are commonly present in patients with SLE. Among the most frequently tested antibodies are antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, and anti-Smith (anti-Sm) antibodies. The presence of these antibodies, especially in high titers, is suggestive of SLE, but it is essential to interpret the results in conjunction with the clinical findings [10].

Other laboratory tests may also include:

1. **Complete Blood Count (CBC):** This test helps identify hematological abnormalities such as anemia or thrombocytopenia.
2. **Urinalysis:** Evaluation of the urine is essential to assess for renal involvement, as SLE can lead to glomerulonephritis.
3. **Complement Levels:** Complement proteins such as C3 and C4 may be depressed in active SLE, indicating disease activity.
4. **Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP):** These inflammatory markers can be elevated in various conditions, including SLE, helping indicate the presence of inflammation [10].

### Challenges in Diagnosis

Despite robust diagnostic criteria, several challenges exist in the assessment of SLE patients. The variation in symptoms can lead to misdiagnosis or delays in treatment, particularly since many of the presenting symptoms overlap with other autoimmune or inflammatory conditions. In some cases, patients present with nonspecific symptoms such as fatigue, which may not raise immediate suspicion for SLE.

Moreover, women of childbearing age may experience symptoms that are masked by hormonal

fluctuations, complicating the diagnostic process further. Therefore, a high index of suspicion is necessary, particularly for individuals presenting with a constellation of symptoms that may suggest an underlying autoimmune process [10].

### **Pharmacological Management of SLE:**

Systemic lupus erythematosus (SLE) is a complex, multifaceted autoimmune disease characterized by the production of a wide array of autoantibodies and the involvement of multiple organ systems. Its pathophysiology is underpinned by genetic, environmental, hormonal, and immunological factors that lead to a loss of self-tolerance and heightened immune response against host tissues. SLE can present with a variety of symptoms ranging from mild skin rashes to severe complications involving the kidneys, cardiovascular system, and central nervous system. Due to the heterogeneous nature of the disease, pharmacological management requires a nuanced and individualized approach [11].

The treatment of SLE involves a combination of medications aimed at reducing disease activity, alleviating symptoms, and preventing flares. The therapeutic arsenal includes non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids, and immunosuppressive agents. Additionally, newer biologic therapies and targeted synthetic drugs have emerged in recent years, broadening the scope of available treatments. The choice of medication is typically influenced by the severity of the disease, the specific organ systems involved, and the patient's unique clinical presentation as well as any contraindications they may have [11].

NSAIDs are often the first line of defense in managing mild symptoms, such as arthralgia and fever, associated with SLE. These drugs function by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), leading to a reduction in the production of prostaglandins and other inflammatory mediators. Commonly used NSAIDs in SLE include ibuprofen, naproxen, and meloxicam. While generally effective for symptomatic relief, their use must be carefully monitored, particularly in patients with underlying renal compromise or gastrointestinal risks, as long-term use can lead to additional complications, including peptic ulcer disease and renal impairment [12].

Hydroxychloroquine is the most frequently used antimalarial agent in the management of SLE. Originally developed for malaria, its efficacy in treating SLE is attributed to its immunomodulatory properties. Hydroxychloroquine exerts a protective effect on the skin, reduces flares, and has been associated with improvements in serological parameters, including anti-dsDNA antibodies and complement levels. Its mechanism involves the inhibition of toll-like receptors, which play a pivotal role in the activation of autoreactive B cells. The drug is generally well tolerated, with side effects primarily limited to retinal toxicity, which necessitates regular ophthalmological monitoring. Recent studies also suggest that hydroxychloroquine may confer cardioprotective effects, which is particularly relevant given the increased cardiovascular risk in SLE patients [12].

Corticosteroids, such as prednisone, are often employed for their rapid anti-inflammatory and immunosuppressive effects. They are particularly useful in situations of severe disease flares, where a prompt response is critical for preventing irreversible organ damage. Corticosteroids function by modulating the expression of pro-inflammatory genes, leading to decreased inflammation and immune-mediated tissue injury. However, while effective, long-term corticosteroid therapy poses significant risks, including osteoporosis, obesity, diabetes, and hypertension, which may worsen outcomes. Therefore, clinicians aim to use the lowest effective dose for the shortest duration possible, transitioning to other immunosuppressive therapies when feasible [12].

For patients with significant organ involvement or for those with poorly controlled disease despite corticosteroids, additional immunosuppressive agents may be necessary. Drugs such as azathioprine, mycophenolate mofetil (MMF), and cyclophosphamide are commonly utilized for this purpose. Azathioprine and MMF inhibit lymphocyte proliferation and may help with renal manifestations, particularly lupus nephritis. Cyclophosphamide is often reserved for severe cases due to its toxicity profiles, including risk for malignancy and infertility. Monitoring of blood counts and liver function tests is critical during therapy with these agents to mitigate adverse effects [13].

In the past decade, biologic agents targeting specific pathways in the immune response have revolutionized the management of SLE. Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), has demonstrated efficacy in reducing disease activity in patients with active SLE. Another investigational agent is anifrolumab, which targets the type I interferon receptor and has shown promise in patients with moderate to severe disease. The advent of these targeted therapies underscores the trend towards precision medicine in SLE management [13].

The management of SLE is not solely contingent upon the initiation of pharmacotherapy; ongoing assessment and adjustment are paramount. Regular monitoring through clinical evaluations, laboratory tests, and imaging studies forms the backbone of effective SLE management. Clinicians assess parameters such as renal function, complete blood counts, liver enzymes, and specific autoantibody levels to evaluate disease activity and treatment efficacy. Furthermore, the identification of triggers or exacerbating factors—such as sun exposure, infections, and stress—is crucial in optimizing management strategies. Patients must be educated about self-care measures including sun protection, adherence to medications, and recognition of early flare symptoms [14].

#### Symptom Management and Patient Education:

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the body's immune system attacking its own tissues, leading to widespread inflammation and damage to various organ systems. Patients suffering from SLE often experience a variety of symptoms, ranging from fatigue and joint pain to skin rashes and renal complications. The complexity of SLE, with its unpredictable flare-ups and diverse manifestations, necessitates a multifaceted approach to symptom management and a robust patient education framework. Effective strategies can significantly enhance the quality of life for affected individuals while promoting better disease outcomes [15].

#### Understanding SLE Symptoms

SLE presents with a heterogeneous array of symptoms that can vary significantly from one individual to another. Common symptoms include:

1. **Fatigue:** Often reported as one of the most debilitating symptoms, fatigue in SLE can be persistent and resistant to rest.
2. **Joint Pain:** Arthralgia or joint pain is prevalent and may affect multiple joints, leading to decreased mobility and function.
3. **Skin rashes:** The characteristic "butterfly" rash across the cheeks and nose is a hallmark of SLE, but patients may also experience discoid rashes and photosensitivity.
4. **Renal Issues:** Lupus nephritis, an inflammation of the kidneys, can lead to severe complications, including kidney failure if not managed effectively.
5. **Neurological Symptoms:** Cognitive dysfunction, headaches, and mood disorders can occur, impacting patients' emotional and psychological well-being [16].

Given this complex symptomatology, individualized treatment strategies tailored to the specific needs of the patient are paramount.

#### Symptom Management Strategies

Effective symptom management for SLE often involves a combination of pharmacological treatment, lifestyle modifications, and alternative therapies. A comprehensive approach includes the following elements:

1. **Pharmacological Interventions:**
  - **Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):** Commonly prescribed to alleviate pain and inflammation, NSAIDs are often the first line of treatment for joint pain.
  - **Antimalarials:** Drugs such as hydroxychloroquine not only manage skin and joint symptoms but also have been shown to improve overall outcomes and reduce flares.
  - **Corticosteroids:** These are employed for acute management of severe symptoms and are effective in rapidly reducing inflammation. However, long-term use must be carefully monitored due to side effects.
  - **Immunosuppressants:** Medications like azathioprine and mycophenolate

mofetil may be used in cases of severe SLE, particularly when vital organs are involved [17].

## 2. **Lifestyle Modifications:**

- **Diet:** A balanced diet rich in nutrients can strengthen the immune system. Omega-3 fatty acids, found in fish and flaxseeds, may help reduce inflammation. Additionally, limiting processed foods high in sugar and fat can support overall health.

- **Exercise:** A regular, low-impact exercise regimen can help counteract fatigue, maintain joint flexibility, and improve overall mood. Activities like yoga and swimming are often recommended.

- **Sleep Hygiene:** Proper rest is crucial for managing fatigue. Patients should establish a regular sleep routine and create a conducive sleep environment to enhance sleep quality [18].

## 3. **Alternative Therapies:**

- **Physical Therapy:** Tailored physical therapy regimens can improve joint function and reduce pain.

- **Mindfulness and Stress Management:** Techniques such as meditation, deep breathing exercises, and cognitive-behavioral therapy (CBT) can help manage the emotional burden of chronic illness.

## **The Role of Patient Education**

Patient education plays a critical role in the management of SLE, empowering patients to take an active role in their health care. Effective education encompasses various aspects, including:

1. **Understanding the Disease:** Establishing a solid understanding of SLE, its symptoms, and its course of treatment helps patients recognize warning signs and understand the importance of compliance with their medication regimens [19].

2. **Recognizing Flare Triggers:** Educating patients about common triggers for flare-ups, such as excessive sun exposure, stress, and infections, can enable them to modify their behavior and mitigate potential exacerbations.

3. **Medication Management:** Patients should be informed about the importance of adherence to

prescribed therapies and educated on how to manage side effects. This includes understanding when to seek medical advice and the potential dangers of abrupt discontinuation of medication [20].

4. **Self-Monitoring:** Patients should be taught to self-monitor their symptoms and maintain a diary to track fluctuations that may correlate with lifestyle choices, making it easier to identify patterns or triggers.

5. **Support Resources:** Patients ought to be made aware of support groups, counseling services, and educational resources to foster a sense of community and reduce feelings of isolation [20].

## **Monitoring Disease Activity and Complications:**

Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease that can affect virtually any organ system in the body. Characterized by its unpredictable course and the potential for severe morbidity, SLE poses substantial challenges not only to patients but also to healthcare providers. Due to its heterogeneous nature, effective management of SLE demands meticulous monitoring of disease activity and complications [21].

SLE is a multifactorial condition influenced by genetic, environmental, and hormonal factors. It predominantly affects women of childbearing age, with a notable prevalence among African American and Hispanic populations. The clinical manifestations of SLE can vary widely, ranging from skin rashes, arthritis, and fatigue to severe organ involvement such as nephritis, neuropsychiatric disorders, and vasculitis. The complexity of SLE is exacerbated by its episodic nature; patients often experience flares of disease activity, interspersed with periods of remission.

Monitoring disease activity in SLE is essential for several reasons. Firstly, it allows clinicians to make informed decisions regarding treatment adjustments aimed at minimizing flares and preventing organ damage. Secondly, regular assessments provide patients with an understanding of their disease trajectory, fostering a collaborative approach to management. Thirdly, monitoring is crucial in research settings, where scientists must evaluate the efficacy of new therapeutics [22].

There are several established tools for assessing disease activity in SLE. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is

among the most widely used metrics. The SLEDAI considers various clinical and laboratory parameters, including joint involvement, serological markers, and major organ systems affected. Another important instrument is the European Consensus Lupus Activity Measurement (ECLAM), which similarly evaluates both clinical symptoms and laboratory findings. While these tools provide a quantitative measure of disease activity, the subjective nature of some symptoms, such as fatigue and pain, emphasizes the relevance of clinical judgment [23].

### Common Complications of SLE

SLE is associated with a range of complications that can drastically affect morbidity and mortality. Understanding and monitoring these complications is vital for improving patient outcomes. Here are some of the most significant complications encountered in SLE:

1. **Lupus Nephritis:** One of the most severe manifestations of SLE, lupus nephritis affects approximately 40% to 50% of patients. It is characterized by inflammation of the kidneys, which can lead to renal failure if not promptly addressed. Monitoring renal function, urinary protein levels, and the presence of anti-DNA antibodies is crucial in managing this complication [24].

2. **Cardiovascular Disease:** Patients with SLE have an increased risk of developing cardiovascular complications, including atherosclerosis, which can lead to myocardial infarction and stroke. Monitoring lipids, blood pressure, and inflammatory markers can help mitigate this risk. Regular assessments of cardiovascular health and lifestyle adjustments are recommended.

3. **Neurological Manifestations:** Neuropsychiatric manifestations of SLE can include seizures, psychosis, and cognitive dysfunction. These symptoms can be challenging to assess due to their subjective nature. Neurocognitive screening tools and MRI are useful adjuncts to clinical evaluations, aiding in detecting subtle changes in brain function.

4. **Infections:** Patients with SLE are at heightened risk of infections due to both the disease itself and the immunosuppressive therapies frequently employed. Careful monitoring for signs

of infection, along with appropriate vaccinations and prophylactic measures, is essential.

5. **Malignancy:** Research suggests that patients with SLE have an increased risk of certain malignancies, particularly lymphoproliferative disorders. Regular screening for cancers, especially in patients on immunosuppressive therapies, is advised [24].

### Implications for Patient Management

The implications of monitoring disease activity and complications in SLE are far-reaching. Effective monitoring enables healthcare providers to tailor treatment plans that minimize disease activity while addressing complications proactively. This approach not only improves clinical outcomes but also enhances the quality of life for patients, who often grapple with the chronic nature of their disease [25].

Communication between patients and healthcare providers is crucial in establishing a comprehensive monitoring strategy. Patients should be encouraged to report any new symptoms or changes in their condition, as early detection of disease flares can lead to prompt intervention. Education on self-monitoring techniques, including regular blood pressure checks and symptom diaries, can empower patients to take an active role in their care.

Additionally, the multidisciplinary approach involving rheumatologists, nephrologists, cardiologists, and mental health professionals can lead to more comprehensive management. This collaboration ensures that all aspects of a patient's health are considered, thereby reducing the likelihood of complications and improving patient outcomes [26].

### Psychosocial Support for SLE Patients:

Systemic Lupus Erythematosus (SLE) is a complex, chronic autoimmune disease characterized by an array of symptoms that can affect multiple body systems, including the skin, joints, kidneys, heart, and nervous system. Given its unpredictable nature and the potential for severe health complications, SLE can significantly impact patients' emotional and psychological well-being. As such, psychosocial support is crucial in managing the illness.

SLE is often considered more than a physical ailment; it is a chronic stressor that can affect nearly

every aspect of a patient's life. The disease manifests through unpredictable flare-ups and remissions, leading to anxiety regarding health uncertainties. Symptoms such as fatigue, joint pain, skin rashes, and kidney complications can vary in intensity, making daily functioning problematic. Furthermore, patients may experience misunderstandings from family, friends, and co-workers about the invisible nature of their pain, leading to social stigmatization and isolation. Psychological issues such as depression, anxiety, and low self-esteem are prevalent among SLE patients, largely due to chronic pain and the limitations imposed by the condition. Consequently, psychosocial support becomes an essential aspect of holistic care for these individuals [27].

### The Role of Psychosocial Support

Psychosocial support can be defined as a continuum of assistance that addresses both psychological and social needs and encompasses emotional support, practical assistance, and information provision. Such support helps SLE patients cope with the emotional toll of the disease and improves their overall quality of life [28].

1. **Emotional Support:** A critical component of psychosocial support involves providing emotional reassurance and understanding to SLE patients. This can take many forms, including providing a listening ear to those who wish to share their experiences, validating their feelings, and serving as advocates for their needs. Support groups specifically for SLE can offer an environment where individuals share their struggles and strategies. Such peer support can combat feelings of isolation, increase hopefulness, and foster resilience [29].

2. **Informational Support:** Knowledge about SLE is empowering. Healthcare professionals have a duty to furnish patients with comprehensive information regarding their condition, treatment options, and potential lifestyle changes. Equipping patients with knowledge helps alleviate anxiety about the unknown, allowing for better management of the disease. Educational workshops or seminars led by healthcare providers can be valuable resources for both patients and families [30].

3. **Practical Support:** Many SLE patients encounter practical challenges, such as difficulty maintaining employment due to fatigue or requiring help with daily activities during flare-ups. Providing

practical support—through organizational assistance, connecting patients with community resources, or advocating for reasonable workplace accommodations—can facilitate a sense of normalcy and promote autonomy.

4. **Psychological Interventions:** Professional mental health services can play a paramount role in addressing the psychological aspects of living with SLE. Cognitive Behavioral Therapy (CBT) has shown efficacy in helping patients develop better coping strategies, manage depressive symptoms, and challenge negative thought patterns. Additionally, mindfulness-based stress reduction and relaxation techniques can aid patients in managing anxiety and improving overall mental well-being [31].

### The Importance of a Comprehensive Support Network

For effective psychosocial support, a comprehensive network involving family, healthcare providers, and community resources is vital. Family members serve as the first line of support and can play an integral role in a patient's coping process. Educating family members about SLE can foster understanding and help them provide appropriate emotional and practical support [32].

Healthcare providers also have a significant role in integrating psychosocial care into routine medical treatment. Encouragement to seek mental health services and providing referrals can contribute to a supportive treatment environment. Furthermore, the establishment of multidisciplinary teams—including rheumatologists, psychologists, social workers, and nutritionists—can ensure that SLE patients receive well-rounded care that addresses both their physical and psychosocial needs [33].

Community resources, including local nonprofit organizations or virtual support groups, can be invaluable for patients seeking connection with others who understand their plight. These resources often provide educational materials, access to counseling, and opportunities for socialization that foster a sense of community and belonging.

Despite the evident benefits of psychosocial support, several challenges exist in its provision. Stigma surrounding mental health struggles may deter patients from seeking help, while time constraints in clinical settings can limit healthcare providers'



ability to offer comprehensive psychosocial support. Additionally, access to mental health services can be hampered by financial limitations or geographical barriers, particularly for patients living in rural or underserved communities [34].

Furthermore, the variability of SLE symptoms means that the psychosocial needs of patients may fluctuate over time, necessitating an adaptable approach. There is no one-size-fits-all when it comes to providing psychosocial support for SLE patients; strategies must be tailored to meet individual needs and circumstances [35].

### **Lifestyle Considerations for SLE Management:**

Systemic Lupus Erythematosus (SLE) is a complex, chronic autoimmune disease characterized by the immune system's abnormal response, resulting in inflammation and damage to various tissues and organs. Unlike other health conditions, effective management of SLE often goes beyond pharmacological interventions, necessitating a holistic approach that incorporates lifestyle modifications. Through strategic changes in diet, physical activity, stress management, and daily habits, individuals with SLE can significantly improve their quality of life and potentially mitigate disease flares [36].

### **Understanding SLE and Its Implications**

SLE predominantly affects women of childbearing age, although it can manifest in individuals of any gender or age. The symptoms vary widely, ranging from mild fatigue and joint pain to severe complications involving the kidneys, heart, or nervous system. The unpredictable nature of the disease can lead to periods of remission followed by exacerbation, known as flares. Therefore, effective management is essential, prioritizing symptom control and minimizing the risk of complications [37].

### **The Role of Diet**

Nutrition plays a crucial role in managing SLE. A well-balanced diet rich in anti-inflammatory foods can help alleviate symptoms and enhance overall health. Key dietary considerations include:

1. **Incorporating Fruits and Vegetables:** Antioxidant-rich fruits and vegetables, such as berries, leafy greens, and cruciferous vegetables, can combat oxidative stress and inflammation. These

foods are high in vitamins C and E and various phytonutrients, which are beneficial for immune support [38].

2. **Healthy Fats:** Omega-3 fatty acids, found in fatty fish (e.g., salmon, mackerel), flaxseeds, and walnuts, exhibit anti-inflammatory properties. Consuming these fats in moderation can help manage inflammation associated with SLE.

3. **Avoiding Processed Foods:** Refined sugars and carbohydrates, as well as highly processed foods high in saturated fats, can exacerbate inflammatory responses in the body. A diet high in whole grains, lean proteins, and healthy fats is advocated.

4. **Hydration:** Individuals with SLE are at an increased risk for kidney issues. Maintaining proper hydration is essential for kidney function and overall health, which necessitates regular intake of water throughout the day [39].

5. **Limiting Sodium:** High sodium intake can exacerbate hypertension—a common concern for those with SLE. Opting for low-sodium alternatives while cooking and choosing fresh produce over canned goods can help manage blood pressure.

### **Physical Activity and Its Benefits**

Regular physical activity is vital for maintaining overall health and managing SLE. Regular exercise helps improve cardiovascular health, reduce fatigue, and combat depression and anxiety. However, due to the fatigue and joint pain often associated with SLE, individuals must approach exercise cautiously:

1. **Low-Impact Activities:** Engaging in low-impact exercises such as walking, swimming, cycling, and yoga can foster flexibility, strength, and endurance without placing undue stress on the joints [40].

2. **Tailored Exercise Regimens:** Consulting with healthcare providers or physical therapists can help create personalized exercise plans that account for individual activity levels, abilities, and current symptomatology.

3. **Gradual Increase:** Starting slow and gradually increasing activity intensity allows individuals to build stamina while avoiding potential flares that might arise from overexertion [40].

### Stress Management

SLE can be exacerbated by stress, making effective stress management techniques essential for patients navigating the complications of the disease. Various approaches can help mitigate stress:

1. **Mindfulness and Meditation:** Mindfulness practices allow individuals to focus on the present moment, fostering relaxation and reducing anxiety. Techniques such as deep-breathing exercises, meditation, and progressive muscle relaxation can enhance mental well-being.
2. **Therapeutic Pursuits:** Engaging in hobbies, art, or other recreational activities can serve as an effective outlet for stress relief. Finding time for passions or interests can enhance life satisfaction and lessen the burden of chronic illness.
3. **Social Support:** Building a support network, whether through friends, family, or support groups, can provide emotional assistance and a sense of community. Connecting with others facing similar challenges can impart valuable insights and foster resilience [41].

### Sleep Hygiene

Quality sleep is crucial for self-management of SLE. The fatigue commonly experienced by individuals with lupus can be compounded by poor sleep quality. To promote better sleep:

1. **Routine and Consistency:** Establishing a consistent sleep schedule empowers the body to regulate its internal clock, optimizing restorative sleep.
2. **Sleep Environment:** Creating a calming and darkened sleep environment, supplemented with comfortable bedding, can encourage relaxation and promote more effective rest.
3. **Limiting Stimulants:** Reducing intake of caffeine and other stimulants, especially in the latter parts of the day, can facilitate better sleep quality [42].

### Avoiding Triggers

Individuals with SLE can identify and avoid environmental triggers that might precipitate flares. Common triggers include excessive sunlight, infections, and certain medications. Special considerations include:

1. **Sun Protection:** Wearing protective clothing, using sunscreen with a high SPF, and seeking shade during peak hours can prevent skin rashes and systemic flares induced by UV exposure.
2. **Infection Prevention:** Practicing good hygiene, getting vaccinated as advised, and avoiding crowded places during flu season can substantially reduce the risk of infections that may trigger SLE flares.
3. **Medication Management:** Patients should communicate regularly with healthcare providers about any adverse reactions or concerns regarding medications, including hormonal changes that could influence lupus activity [43].

### Nursing Interventions: Best Practices and Protocols:

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by the inappropriate activation of the immune system, leading to widespread inflammation and damage to various organs, including the skin, joints, kidneys, and nervous system. Nursing interventions play a crucial role in managing SLE by helping to alleviate symptoms, promote patient education, and provide supportive care [44].

### Understanding the Disease

To provide effective nursing care for patients with SLE, it is imperative to understand its pathophysiology, common manifestations, and potential complications. SLE can present with a variety of symptoms, including joint pain, fatigue, skin rashes (most notably the butterfly rash), renal impairment, and neurological disturbances. There is a significant risk for flare-ups, characterized by exacerbations of these symptoms, and patients may also be at increased risk for infections due to immunosuppressive therapies.

Effective nursing practices prioritize an individualized approach to care, taking into account the unique manifestations of the disease in each patient [45].

### Comprehensive Assessment

A foundational step in nursing intervention for SLE is conducting a thorough assessment. This includes obtaining a detailed medical history, identifying the nature and extent of symptoms, and monitoring vital signs. The nurse must assess the patient's pain level,

fatigue, and any physical limitations that may be present due to joint disorders or organ involvement. Regular monitoring of laboratory results is also essential, particularly for those undergoing treatment with immunosuppressive medications or experiencing kidney involvement.

In addition to the physical examination, psychosocial assessment is equally crucial. SLE can have significant psychological and emotional impacts, including anxiety and depression. By addressing mental health concerns, nurses can enhance the overall well-being of patients, facilitating a more comprehensive approach to their care [46].

### Patient Education

Education is a key nursing intervention that empowers patients to manage their condition more effectively. Nurses should provide information about the disease process, treatment options, and lifestyle modifications that can help reduce symptoms and prevent flare-ups. Topics of education can include:

1. **Understanding SLE:** Explaining the nature of the autoimmune response, potential complications, and the chronic aspect of the disease helps patients develop realistic expectations about their condition [47].
2. **Medication Management:** Clear instructions regarding prescribed medications—particularly antimalarials and corticosteroids—are vital. Nurses should educate patients on the importance of adhering to medication schedules, potential side effects, signs of infection, and what to do in case of missed doses.
3. **Recognizing Symptoms of Flare-Ups:** Teaching patients to identify early symptoms of flares enables proactive management. Nurses can provide resources on maintaining a symptom diary to track patterns that precede exacerbations [48].
4. **Lifestyle Modifications:** Encouraging a balanced diet, regular exercise adapted to their physical capabilities, and stress management techniques can promote overall health. Patients should also be educated on the importance of sun protection, as ultraviolet light can trigger skin flare-ups.

5. **Support Systems:** Encouraging engagement with support networks, whether through family, friends, or lupus support groups, fosters an environment of understanding and encouragement [49].

### Symptom Management Protocols

Nursing interventions should also include symptom management protocols tailored to the patient's current presentation. This may involve:

- **Pain Management:** Utilizing pharmacological approaches, such as NSAIDs for pain relief, while also integrating non-pharmacological methods, such as heat therapy or physical therapy, to support joint function.
- **Skin Care:** Nurses should guide patients in proper skincare routines, including the use of emollients and protective measures against sun exposure, thereby reducing the risk of rashes [50].
- **Monitoring for Complications:** Particular attention should be given to renal function, as lupus nephritis is a common complication. Regular monitoring of urine output, blood pressure, and creatinine levels is essential to detect early signs of renal impairment.
- **Nutritional Support:** Providing nutritional counseling to address specific dietary needs and consider any comorbidities, such as hypertension or hyperlipidemia, related to SLE and its treatments [51].

### Psychosocial Support

Given the emotional toll of living with a chronic illness, nurses play a vital role in providing psychosocial support. Establishing a trusting nurse-patient relationship allows patients to express their fears and concerns openly. Referring patients to mental health professionals, if necessary, can ensure they receive comprehensive care.

Additionally, being aware of the impact of SLE on family dynamics is essential. Family members may also need education and support to better understand the challenges faced by their loved ones and to learn how best to provide support [52].

### Coordination of Multidisciplinary Care

Lastly, effective nursing interventions in the management of SLE require collaboration with a multidisciplinary team. Regular communication

with physicians, social workers, dietitians, and physical therapists ensures comprehensive patient care. Nurses often serve as the hub of communication among team members, ensuring that all aspects of a patient's care are harmonized and that any changes in the patient's condition are promptly addressed [53].

### Conclusion:

In conclusion, nursing care for patients with systemic lupus erythematosus (SLE) is multifaceted and requires a comprehensive understanding of the disease's complexities. Effective management involves a holistic approach that addresses not only the physical symptoms but also the emotional and psychological challenges faced by patients.

Nurses play a critical role in promoting patient education, encouraging adherence to treatment regimens, and fostering a supportive environment that empowers patients to manage their condition proactively. Through regular assessments and tailored care plans, nurses can help mitigate the complications of SLE and improve the quality of life for affected individuals.

Furthermore, interprofessional collaboration is vital in providing comprehensive care, ensuring that patients receive integrated support from various healthcare providers. As research continues to evolve, ongoing education and training for nurses will be essential in keeping pace with new therapies and best practices in the management of SLE.

By prioritizing patient-centered care, advocating for holistic treatment approaches, and staying informed about advancements in the field, nurses can significantly influence the outcomes for patients with systemic lupus erythematosus, helping them to lead healthier, more fulfilling lives.

### References:

1. Schmajuk G, Yazdany J, Trupin L, Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. *Arthritis Care Res (Hoboken)* 2010;62:386–92.
2. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis* 2010;69:20–8.
3. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613–9.
4. Yazdany J, Gillis JZ, Trupin L, Katz P, Panopalis P, Criswell LA, et al. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. *Arthritis Rheum* 2007;57:593–600.
5. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). *Ophthalmology* 2016;123:1386–94.
6. Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). *Ann Rheum Dis* 2016;75:1615–21.
7. Castillo F, Strait A, Evans M, Kay J, Gianfrancesco M, Izadi Z, et al. Deriving accurate prednisone dosing from electronic health records: analysis of a natural language processing tool for complex prescription instructions [abstract]. *Arthritis Rheumatol* 2019;71 Suppl 10.
8. Feldman CH, Speyer C, Ashby R, Bermas BL, Bhattacharyya S, Chakravarty E, et al. Development of a set of lupus-specific ambulatory care-sensitive, potentially preventable adverse conditions: a Delphi consensus study. *Arthritis Care Res (Hoboken)* 2021;73:146–57.
9. Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. *J Rheumatol* 2016;43:54–65.
10. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al. A quality indicator set for systemic lupus erythematosus. *Arthritis Rheum* 2009;61:370–7.
11. Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid

- beneficiaries in the United States. *Arthritis Care Res (Hoboken)* 2014;66:617–24.
12. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:736–45.
13. Yazdany J, Robbins M, Schmajuk G, Desai S, Lacaille D, Neogi T, et al. Development of the American College of Rheumatology's rheumatoid arthritis electronic clinical quality measures. *Arthritis Care Res (Hoboken)* 2016;68:1579–90.
14. Xiong WW, Boone JB, Wheless L, Chung CP, Crofford LJ, Barnado A. Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis. *Lupus* 2019;28:977–85.
15. National Quality Forum. NQF-endorsed measures for musculoskeletal conditions. 2015.
16. Centers for Disease Control and Prevention. Adult BMI calculator.
17. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. *Lupus* 2010;19:741–3.
18. Quality ID #236 (NQF): controlling high blood pressure.
19. Elimu Informatics. Semantic normalization: beyond traditional terminology mapping.
20. University of Wisconsin Department of Medicine. Neighborhood atlas.
21. Yazdany J, Trupin L, Schmajuk G, Katz PP, Yelin EH. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. *BMJ Qual Saf* 2014;23:659–66.
22. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: Relationship to ethnicity and country of birth. *Arthritis Rheum.* 38 (1995) 551–558. doi: 10.1002/art.1780380415.
23. Spelman K, Burns JJ, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional medicines: A review of herbal immunomodulators. *Altern. Med. Rev.* 11 (2006) 128–150. doi: 10.1016/j.cyto.2017.10.019.
24. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. *Semin. Arthritis Rheum.* 39 (2010) 257–268. doi: 10.1016/j.semarthrit.2008.10.007.
25. Jammes JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. *Arthritis Rheum.* 44 (2001) 1122–6.
26. Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The incidence and prevalence of systemic lupus erythematosus, 2002–2004: The Georgia lupus registry. *Arthritis Rheumatol.* 66 (2014) 357–368. doi: 10.1002/art.38239.
27. Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. *J. Autoimmun.* 64 (2015) 125–136. doi: 10.1016/j.jaut.2015.08.004.
28. Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. *Nat. Rev. Rheumatol.* 12 (2016) 716–730. doi: 10.1038/nrrheum.2016.186.
29. Helms CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum.* 58 (2008) 15–25. doi: 10.1002/art.23177.
30. Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ. Population-based incidence and prevalence of systemic lupus erythematosus: The Michigan lupus epidemiology and surveillance program. *Arthritis Rheumatol.* 66 (2014) 369–378. doi: 10.1002/art.38238.

31. Ferucci ED, Johnston JM, Gaddy JR, Sumner L, Posever JO, Choromanski TL, Gordon C, Lim SS, Helmick CG. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007–2009. *Arthritis Rheumatol.* 66 (2014) 2494–2502. doi: 10.1002/art.38720.
32. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, Karlson EW. Cigarette Smoking and the Risk of Systemic Lupus Erythematosus: A Meta-Analysis. *Arthritis Rheum.* 50 (2004) 849–857. doi: 10.1002/art.20049.
33. Danchenko N, Satia J, Anthony M. Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden. *Lupus.* 12 (2006) 308–318.
34. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. *J. Rheumatol.* 19 (1992) 265–9.
35. Blomberg J, Nived O, Pipkorn R, Bengtsson A, Erlinge D, Sturfelt G. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: Correlation with autoantibodies and clinical manifestations. *Arthritis Rheum.* 37 (1994) 57–66.
36. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. *Ann.*
37. Crow MK. *Etiology and Pathogenesis of Systemic Lupus Erythematosus.* Tenth Edit, Elsevier Inc, 2017. doi: 10.1016/B978-0-323-31696-5.00079-6.
38. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. *Proc. Natl. Acad. Sci. U. S. A.* 107 (2010) 9813–9818.
39. Roberts AL, Malspeis S, Kubzansky LD, Feldman CH, Chang S-C, Koenen KC, Costenbader KH. Association of Trauma and Posttraumatic Stress Disorder With Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women. *Arthritis Rheumatol.* (Hoboken, N.J.) 69 (2017) 2162–2169. doi: 10.1002/art.40222.
40. Katsuyama T, Tsokos GC, Moulton VR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. *Front. Immunol.* 9 (2018).
41. Thompson RA, Haeney M, Reid KBM, Davies JG, White RHR, Cameron AH. A Genetic Defect of the C1q Subcomponent of Complement Associated with Childhood (Immune Complex) Nephritis. *N. Engl. J. Med.* 303 (1980) 22–24. doi: 10.1056/NEJM198007033030107.
42. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 25 (1982) 1271–1277. doi: 10.1002/art.1780251101.
43. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M. Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA Peptide Complexes in Systemic Lupus Erythematosus. *Sci. Transl. Med.* 3 (2011) 73ra19–73ra19. doi: 10.1126/scitranslmed.3001180.
44. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci. Transl. Med.* 3 (2011). doi: 10.1126/scitranslmed.3001201.
45. Casciola-Rosen L, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. *J. Exp. Med.* 179 (1994) 1317–1330. doi: 10.1084/jem.179.4.1317.
46. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MGE, Ly N, Woodward RN, Fry KE, Lau AY-H, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon- $\gamma$ -induced genes in systemic lupus erythematosus. *Arthritis Rheum.* 50 (2004) 3958–3967.
47. Paidassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehwet B, Gaboriaud C,

- 
- Arlaud GJ, Frachet P. C1q Binds Phosphatidylserine and Likely Acts as a Multiligand-Bridging Molecule in Apoptotic Cell Recognition. *J. Immunol.* 180 (2008) 2329–2338. doi: 10.4049/jimmunol.
48. Bastian HM, Roseman JM, Mcgwin G, Alarcón GS, Friedman AW, Fessler BJ, Baethge BA, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. *Lupus.* 11 (2002) 152–160. doi: 10.1191/0961203302lu158oa.
49. Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. *Lupus.* 21 (2012) 241–250. doi: 10.1177/0961203311426568.
50. Petri M, Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. *Arthritis Care Res.* 8 (1995) 137–45.
51. Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. *J. Am. Acad. Dermatol.* 72 (2015) 634–639. doi: 10.1016/j.jaad.2014.12.025.
52. Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T, Lehmann P. Phototesting in lupus erythematosus: a 15-year experience. *J. Am. Acad. Dermatol.* 45 (2001) 86–95. doi: 10.1067/mjd.2001.114589.
53. Olsson SW, Lee JJ, Prince LK, Baker TP, Papadopoulos P, Edison J, Abbott KC. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. *Clin. J. Am. Soc. Nephrol.* 8 (2013) 1702–1708. doi: 10.2215/CJN.01910213.